Skip to main content

Table 2 Summary of survival outcomes stratified by recurrent versus de novo status

From: Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study

 

Univariable Analysis

Multivariable Analysis

PDAC population

Overall survival (months)

95% CI

HR

95% CI

P-value

HR

95% CI

P-value

Recurrent

10.8

9.9–11.7

Reference

Reference

De Novo

7.3

7.0–7.7

1.48

1.37–1.6

 < 0.001

1.2

1.1–1.3

 < 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us